Summary We have evaluated the value of specific bone resorption markers in monitoring metastatic bone disease to define the duration of action of a single high-dose pamidronate infusion. Twenty patients received a single infusion of pamidronate 120 mg for painful bone metastases. Ten out of these 20 patients also received a second infusion. They were evaluated at baseline, 2, 4 and 8 weeks after each infusion. A composite pain questionnaire, serum and urine tests were carried out at these time points. Bone resorption markers measured included urinary calcium, hydroxyproline and two new markers: pyridinoline and deoxypyridinoline. Reference values were defined by 20 healthy controls matched by age and sex. Pamidronate induced a profound fall in bone resorption with a maximal effect within the first month after therapy. Changes in urinary calcium levels were confounded by a rise of 100% in the parathyroid hormone levels. Before treatment, pyridinoline and deoxypyridinoline were increased in 70% of patients, while urinary calcium was increased in only 40% of them. Thirteen patients had a > 50% fall in deoxypyridinoline levels and were considered as biochemical responders. These patients had a mean reduction in pain score of about 30% of baseline levels, which was significantly higher than the seven non-biochemical responders. In conclusion, urinary calcium is not a precise marker of bone resorption. Deoxypyridinoline seems to be the most specific bone resorption marker in cancer patients. Biochemical responders have the most benefit from pamidronate in terms of pain relief. This suggests that patients may benefit from more potent or repeated infusions of bisphosphonates.
Bone is the most common site for metastases from breast and prostate cancer, affecting about 70% of patients with metastatic disease. These metastases cause considerable morbidity including bone pain, hypercalcaemia, pathological fractures, nerve root/spinal cord compression and consequently a decrease in mobility and quality of life. Palliation of symptoms and improvement in quality of life are the major therapeutic goals in metastatic bone disease.
Our understanding of the pathophysiology of bone metastases has increased in the last few years. The most important mechanism of bone destruction is the release of paracrine factors (cytokines, growth factors, prostaglandins), which stimulate osteoclasts to resorb bone (Boyce, 1991) . There is some recent evidence that bone is itself an important source of growth factors, which following release during bone resorption, may stimulate tumour growth (Garret, 1993) , creating a stimulatory vicious circle in the bone microenvironment.
Bisphosphonates are agents that inhibit osteoclastic bone resorption in several ways and might be able to disrupt this cycle. They may have a direct cytotoxic effect on osteoclasts, inhibit the migration and transformation of osteoclast precursors into mature osteoclasts and impede the attachment of osteoclasts to the bone surface (Flanagan and Chambers, 1989; Lowik et al., 1988) .
Bisphosphonates are increasingly being prescribed for patients with bone metastases. They are the treatment of choice in hypercalcaemia of malignancy and may be used in the management of bone pain from bone metastases. They are also able to prevent skeletal complications such as pain requiring radiotherapy, reduce the incidence of hypercalcaemia and pathological fractures (Van Holten-Verzantvoort et al., 1993; Paterson et al., 1993; Lahtinen et al., 1992) and, when associated with chemotherapy, increase the median time to disease progression in bone (Conte et al., 1994) .
There is uncertainty about the ideal schedule of pamidronate in metastatic bone disease because of the difficulty in monitoring its effects. Measurement of bone turnover by biochemical markers is perhaps a more objective method to evaluate the effects of bisphosphonates on bone. Urinary calcium (uCa) has traditionally been used to evaluate bone resorption (Campbell et al., 1983) and is considered the standard bone resorption marker in oncology, although it does not exclusively reflect bone resorption. Hydroxyproline (Hyp) is another traditional bone resorption marker that has been used to evaluate pharmacological effects on bone turnover, but has its own sources of inaccuracy (Coleman et al., 1988) .
There is a clear need for more reliable and specific markers of bone resorption. In the last few years, new products of collagen breakdown, which are released into the circulation during bone resorption, have been identified as bone resorption markers. They are the naturally fluorescent non-reducible cross-links of collagen: deoxypyridinoline and pyridinoline (Eyre et al., 1984) . Their function is to stabilise the collagen fibrils by forming bridge linkages (cross-links) with neighbouring collagen molecules (Eastell, 1994) . Pyridinoline is also found in cartilage, ligament, tendons, vessels and can be released from the tumour stroma whereas deoxypyridinoline is found in significant amounts only in bone and therefore is highly bone-specific (Eyre, 1992) . Cross-links are not influenced by diet (Colwell et al., 1993) , probably not metabolised, and excreted in the urine. They have primarily been tested in Paget's disease of bone and osteoporosis. Oncology is a new area of application for these markers. We have previously reported preliminary results on the use of urinary excretion of pyridinium crosslinks for monitoring metastatic bone disease (Coleman et al., 1992) .
Pamidronate is the most potent bisphosphonate in clinical use. Our group has previously reported the clinical results of this trial of high-dose pamidronate elsewhere (Purohit et al., 1994) . The aims of this study were to confirm the value of specific resorption markers in monitoring metastatic bone disease and define the duration of action of a single pamidronate infusion. All patients received an infusion of pamidronate 120 mg and were followed up over 8 weeks. Ten patients subsequently received a second infusion with the same dose for recurrence of bone pain. This second infusion was given with a median of 6 weeks (range 2 -10) after the 8 weeks follow-up of the first treatment. Pamidronate was given over 12 hours in 11 normal saline and subjects were followed up in the out-patient department.
Biochemical analysis A fasting morning serum sample and a second voided urine sample were collected at baseline, 2, 4 and 8 weeks after both treatments and stored at -20°C. The urine was acidified with 3% hydrochloric acid before storage. All samples from an individual were analysed in duplicate and in the same batch to minimise interassay variation.
Routine serum measurements included full blood count (FBC), serum calcium (sCa) corrected for albumin, phosphate (P04), creatinine, urea, parathyroid hormone (PTH) and total alkaline phosphatase. Two bone formation markers were also measured: osteocalcin (Oc) and bone alkaline phosphatase (bAP).
Intact PTH was measured by a two-site immunoradiometric assay (Allegro PTH, Nichols Institute, San Juan Capistrano, CA, USA). The detection limit of the assay is 1 pg ml-'. The intra-assay and interassay variability were 5% and 5.5% respectively. Osteocalcin was measured by a two-site immunoradiometric assay that measures intact osteocalcin (1-49 peptides) and the large N-terminal mid-fragment (1 -43 peptides) using human osteocalcin as standard (Elsa-Osteo, CIS, Gif-sur-Yvette, France). Samples may be stored at -20°C for this osteocalcin assay as it is less sensitive to storage conditions than other commercial assays (Blumsohn, 1995a) . This assay is claimed to have less in vitro proteolytic degradation when exposed to room temperature than other assays used to measure osteocalcin (Garnero et al., 1994a) . The detection limit of the assay is 0.4 ng ml-'. The intra-assay and interassay variability were 5.8% and 7% respectively. Bone alkaline phosphatase was measured by a precipitation method that makes use of the affinity of the wheatgerm lectin for the bone isoenzyme (Rosalki and Foo, 1984) . The amount of the bone isoenzyme is calculated by subtracting the total alkaline phosphatase from the supernatant (liver isoenzyme).
Roche uni-kit III was used for analysis with the application of a COBAS machine. The intra-assay and interassay variability were 5.8% and 7% respectively. Urinary creatinine was measured using an automated chemistry analyser using a kinetic Jaffe method and all the urinary markers are expressed as a ratio to creatinine excretion. Urinary calcium was measured by a colorimetric assay. Hydroxyproline was measured by a colorimetric assay with dimethylaminobenzaldehyde after acid hydrolysis and chloramine T oxidation.
Total pyridinoline (Pyd) and deoxypyridinoline (Dpd) were measured in duplicate after acid hydrolysis, CFI cellulose column partition chromatography, and reverse-phase highperformance liquid chromatography (HPLC) with fluorescence detection (Colwell et al., 1993) . The intra-assay and interassay variability were 8.5% and 12.5% respectively.
Response criteria
At each visit the scores for pain intensity, WHO performance status and analgesic consumption were combined to produce an overall pain score (Coleman, 1994) . Subjective response to treatment was defined as >20% decrease in the pain score compared with the baseline on at least two consecutive measurements. Patients with pain decrease <20% were considered non-subjective responders (Purohit et al., 1994) . Biochemical response to treatment was defined as > 50% decrease in the deoxypyridinoline (which is the most bonespecific resorption marker) value compared with the baseline value. Patients with <50% decrease in the deoxypyridinoline values were considered as non-biochemical responders. This value was chosen because this is the usual cut-off point between response or not to treatment in cancer patients.
Statistical methods
Most markers showed a skewed distribution, so the data were logarithmically and back transformed, expressed as mean+standard error and shown as the percentage (%) of baseline values of each infusion, except for serum calcium and phosphate which are expressed as mmol 1-'. For comparison of baseline measurements of patients and controls, the unpaired t-test was used. The reference range was defined non-parametrically as between the 2.5% and 97.5% percentiles. A paired t-test with Bonferroni correction was used to compare changes in markers over time. As three comparisons were made, P<0.017 was considered significant. Baseline values of both infusions were compared by the paired t-test with P<0.05 considered as significant. The area under the response curve (AUC) of each marker in both infusions was determined and compared with an AUC assuming no change over the 8 weeks with P < 0.05 considered as significant.
Comparisons between biochemical responders and nonresponders and between first and second infusions were done by multifactor analysis of variance using the Scheffe test. Pearson correlation coefficients between markers at baseline and between AUC after treatment were determined. Pearson correlation was also used to compare percentage of pain score change and percentage decrease in deoxypyridinoline levels.
Results
General biochemistry and haematology Serum calcium showed a significant decrease after the first infusion at 2 and 4 weeks ( Table I ). The AUC for calcium after the first infusion also showed a significant decrease (P<0.003). Serum calcium also fell after the second infusion, but this was not significant. The AUC of serum phosphate fell significantly after both infusions (P< 0.02 after the first infusion and P<0.01 after the second infusion). PTH levels increased at 2 and 4 weeks after the first infusion by > 100%, (Table I) , with every patient showing at least a 20% increase compared with baseline values. The AUC also showed a significant increase (P<0.005). Following the second infusion, PTH increased by 65% at 2 weeks (P<0.01) and by 23% at 4 weeks (NS) ( Table I) .
Bone formation
Baseline values of bone and total alkaline phosphatase were increased significantly, contrasting with osteocalcin results (Table II) . Osteocalcin and bone alkaline phosphatase decreased by 15% at 8 weeks after both infusions, but this was not statistically significant (Figure 1 ). Bone alkaline phosphatase decreased by 30% at 8 weeks after the second infusion compared with the baseline of the first infusion, but this also did not reach statistical significance. There was no correlation between osteocalcin and bone alkaline phosphatase at baseline (r = 0.3) or AUC of the first infusion (r = 0.2).
Bone resorption All resorption markers, except urinary calcium, were increased significantly at the beginning of treatment, with pyridinoline and deoxypyridinoline being the most frequently increased markers (70%). The spread of pretreatment values is shown in Figure 2 . Before the second infusion, only pyridinoline and deoxypyridinoline were significantly increased when compared with controls (t-test). Urinary calcium was increased in only 40% and 20% of patients before the first and second infusions respectively (Table II) . Pamidronate in metastatic bone disease J Vinholes et al 9 1091 Urinary calcium, hydroxyproline, pyridinoline and deoxypyridinoline fell significantly at all time points after the first infusion (Figure 3) . The AUC approach also showed that there was a significant decrease in these markers (P<0.001). After the second infusion, the resorption markers fell significantly at 2 and 4 weeks compared with baseline of this infusion except for hydroxyproline, owing to high interpatient variability. The shape of the curve response of this infusion was similar to the first infusion.
Before The Pyd/Dpd ratio was significantly higher in patients at baseline compared with controls (4.4 vs 3.9 respectively). This ratio increased significantly at 2 weeks to 6.5 and then decreased to 5.7 at 4 weeks and 5.1 at 8 weeks. The effects of each treatment on bone turnover markers over the 8 weeks were compared by multifactor analysis of variance. No significant differences in biochemical effects between the two infusions was identified (P= 0.22). Urinary calcium was excluded from this analysis because its levels were influenced by PTH.
Pain relief and biochemical response Two patients received dexamethasone and radiotherapy, which make the interpretation of the change in the pain score difficult, were considered non-assessable. The mean pain score in the remainder fell at 2 weeks and remained practically unchanged to 8 weeks (Figure 4 ), reflecting the decrease in bone resorption. Before the second infusion, the pain score increased again but fell with retreatment ( Figure   4 ).
Thirteen patients showed a subjective response. Of these, 11 were also biochemical responders. The other two patients only had a 30% reduction in Dpd. Five patients were nonsubjective responders and of these, only two were considered biochemical responders.
In total, there were 13 biochemical responders and seven non-responders. All of the non-responders also showed <50% reduction in pyridinoline and four had <50% reduction in hydroxyproline values, whereas all of them showed > 50% reduction in urinary calcium levels.
Biochemical responders showed a greater relief of pain when compared with non-responders by multifactor analysis of variance (P<0.01) ( Figure 5 ). There was a significant correlation between the maximum decrease in pain score (%) and the maximum decrease (%) in deoxypyridinoline levels (r=0.51, P<0.05). However, changes in pain score did not correlate with changes in any of the other resorption markers.
Seven out of ten patients responded subjectively to treatment after the second infusion. Among these, six were biochemical responders. Three patients did not show pain relief. Among those, two were considered non-biochemical responders.
In the ten patients who received both infusions, baseline levels of bone markers at both infusions were compared. Although there was some carry-over effect from the first infusion (Figure 4) , none of the markers showed a statistically significant difference. Pearson correlation coefficients of the baseline and AUC values after the first infusion are shown in Table III (Coleman and Rubens, 1987; Vinholes et al., 1995) suggest that the maximal effect on bone resorption occurs even earlier than 2 weeks. After two weeks there was a steady progressive increase in bone resorption, but significant inhibition persisted throughout the 8 weeks of observation. The inhibition of bone resorption reduces the release of calcium from the skeleton to the circulation, which was evidenced by the fall in serum calcium after both treatments. A statistically significant fall in the serum calcium of normocalcaemic breast or prostate cancer patients has previously been observed after clodronate (Thiebaud et al., 1991; Martoni et al., 1991) and pamidronate (Lipton et al., 1994) . As calcium homeostasis is tightly controlled by PTH, even relatively small falls in calcium levels, induce a negative feedback in the parathyroid glands within a few minutes. The accuracy of this process is impressive, allowing serum calcium to change only about 0.025 mmol 1-1 during the day (Broadus, 1993) . We observed a marked increase in PTH levels after both infusions, with some effects still persisting at 8 weeks. A significant increase in PTH levels after oral and intravenous (i.v.) pamidronate was also found by other investigators (Reid et al., 1994; Body et al., 1995) and also after i.v. clodronate (Pecherstorfer et al., 1993) . PTH acutely regulates serum calcium by increasing distal renal tubular reabsorption of calcium, hence decreasing urinary calcium excretion. Furthermore, PTH leads to a decrease in distal and proximal renal tubular reabsorption of phosphate, resetting the renal tubular threshold of phosphate at a lower level.
Urinary calcium has been used to measure bone resorption for more than three decades. Most published reports about the effects of bisphosphonates in cancer patients have relied on urinary calcium to monitor bone resorption (O'Rourke et al., 1995) . Although uCa is a cheap and easy to measure assay, it can be influenced by diet, renal function, parathyroid hormone, parathyroid hormone-related protein and seems to reflect the balance of bone turnover, rather than bone resorption specifically (Blomqvist et al., 1987) . Compared with the other resorption markers, relatively few patients had increased baseline values in this trial. This confirms the findings of a recently published study that compared 143 normal controls with 98 cancer patients with bone metastases and showed no significant increase in urinary calcium between cancer patients (mainly breast cancer) with bone metastases and controls (Pecherstorfer et al., 1995) . In addition in our study, within a month after pamidronate, < 10% of patients had abnormal urinary calcium values, while 35% of patients had Dpd levels above the normal range. Therefore, urinary calcium does not seem to be a sensitive marker of bone resorption.
Not surprisingly, urinary calcium did not correlate with any other resorption marker at baseline or by comparison of areas under the curve after both treatments. This lack of correlation with other resorption markers has also been noted in previous studies (Coleman et al., 1992; Body and Delmas, 1992) . This is explained by the fact that urinary calcium is not only monitoring changes in bone turnover, but is also reflecting the renal handling of calcium by PTH whereas cross-links reflect the metabolism of the bone collagen (Seibel et al., 1994) . The absence of correlation of changes in urinary calcium with pain score confirms some recently published data (O'Rourke et al., 1995) .
Hydroxyproline is an imino acid present in significant amount in all collagenous tissues (including bone), elastin and complement factor Clq. It is estimated that about 80% of hydroxyproline is metabolised in the liver by hydroxyproline oxidase and only 10% is excreted in the urine (Eastell, 1994) . Because serum levels of hydroxyproline can be influenced by diet or soft tissue destruction by extraskeletal metastases it does not have the profile of an accurate resorption marker. The fall in hydroxyproline was not statistically significant after the second infusion.
Pyridinoline and deoxypyridinoline were increased in 70% of patients. They have also been shown to be significantly increased in other reports (Coleman et al., 1992; Lipton et al., 1993; Pecherstorfer et al., 1995) . Ninety per cent of patients had mainly osteosclerotic disease, in which bone resorption is not increased as much as it is in lytic or mixed bone metastases.
Pyridinoline and deoxypyridinoline showed a consistent mean decrease of 30% and 42% respectively after both infusions. There was also a significant correlation between Pyd and Dpd at baseline and with treatment using the AUC values, with hydroxyproline, but no correlation with urinary calcium.
The Dpd/Pyd ratio was increased in these patients, which is supported by recent similar findings (Pecherstorfer et al., 1995; Behrens et al., 1995) . This increase may be explained by the fact that many patients also had concomitant soft tissue metastases and it is known that there is a soft tissue component to the urinary excretion of pyridinoline. These soft tissue metastases possibly progressed during the trial as these patients were not receiving any systemic anti-cancer therapy. The decrease in the ratio towards normal after 2 weeks is probably due to the reactivating bone metastases. Dpd showed a greater decrease than Pyd after both infusions, resulting in a significant increase in the Pyd/Dpd ratio after treatment, probably reflecting the higher bone specificity of deoxypyridinoline. Similar observations were made in a previous study on oral pamidronate (Coleman et al., 1992) .
This increased Pyd/Dpd ratio in cancer patients suggests that deoxypyridinoline is a more reliable marker in this situation than pyridinoline.
The changes in pain score seem to follow the changes in resorption markers and suggest that these markers could be used to monitor antiresorptive therapy. At the time of the second treatment when patients had recurrent bone pain, the pamidronate effects on bone resorption had faded away and bone resorption was increasing again. This suggests a positive relationship between increased bone resorption and bone pain and the need of further treatment in responsive patients. The significant, although somewhat weak correlation, between changes in Dpd and pain score also reinforces this possibility. The significantly greater decrease in pain score in patients considered as biochemical responders is interesting and suggests that more potent bisphosphonates that are capable of reducing bone resorption further may be clinically superior to currently available compounds. We have taken 50% as a cut-off point because this is a widely accepted index of markers and biochemical response in clinical oncology and we intend to evaluate this prospectively in a trial in which we are comparing high-dose pamidronate with placebo for painful bone metastases.
Bone formation markers remained unchanged over the first month, beginning to fall at 8 weeks and with some carryover effect to the next dose. Close follow-up over a longer period of time is needed to assess possible clinically important reductions in the rate of bone formation with long-term bisphosphonate use. Bone alkaline phosphatase was elevated in two-thirds of the patients and was a more 1094 sensitive indicator of bone formation than osteocalcin. which was elevated in only 40% of patients at baseline. Interestingly, there was no significant correlation between these formation markers, as previously described (Li et al., 1993) , possibly because bone alkaline phosphatase reflects the synthesis of the organic bone matrix while osteocalcin reflects the mineralisation process. The shape of the time curve response of bone metabolism markers was similar after both infusions. Resorption markers are the first to decrease and are followed by the formation markers about 6-8 weeks later. This reflects the coupling process of bone resorption and formation, in a process known as bone remodelling. The entire process takes about 3-4 months with bone formation only normally occurring in areas of bone undergoing resorption (Mundy, 1995) .
The optimal choice of bone metabolism markers remains an area for debate. Bone Recently, some immunoassays to measure peptide-bound cross-links such as the N-telopeptide-NTX- (Hanson et al., 1992) and the C-telopeptide of type I collagen-Crosslaps- (Garnero, 1994b) have been developed. They have shown a good correlation with deoxypyridinoline and pyridioline and are much easier to measure (Blumsohn et al., 1995b ).
In conclusion, we can confirm that pamidronate is a potent inhibitor of bone resorption in patients with metastatic bone disease. Comparative tnrals of dose, potency and schedule are needed to determine the true relationship between biochemical and clinical effects, but our paper suggests that repeated doses or more potent bisphosphonates may be clinically even more effective. As there is a possibility that a placebo effect could have contnrbuted to the subjective response, we are now carrying out a randomised double-blind placebo-controlled study. Urinary calcium is not a sensitive or specific marker of bone resorption. Deoxypyridinoline seems to be the best resorption marker to monitor therapy, although pain is complex and only partially related to the rate of bone resorption. The availability of specific bone resorption markers will be helpful for selecting and monitoring the optimal schedule of bisphosphonates in cancer patients.
